Treatment of necrolytic migratory erythema in glucagonoma syndrome

Mary E. Shepherd, Sharon S. Raimer, S. K. Tyring, Edgar B. Smith

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

The glucagonoma syndrome is characterized by elevated serum glucagon, a pancreatic α-cell tumor, anemia, hypoaminoacidemia, and necrolytic migratory erythema. Necrolytic migratory erythema may cause marked morbidity and is frequently misdiagnosed. A 42-year-old white woman with a 1½-year history of refractory dermatitis (most severe on the lower extremities) had the glucagonoma syndrome. Her severe morbidity was markedly relieved with the administration of intravenous amino acids. This therapy was successful in controlling the necrolytic migratory erythema through recurrences after somatostatin (SMS 201-995), surgical debulking, and chemotherapy proved inadequate.

Original languageEnglish (US)
Pages (from-to)925-928
Number of pages4
JournalJournal of the American Academy of Dermatology
Volume25
Issue number5
DOIs
StatePublished - Jan 1 1991

    Fingerprint

ASJC Scopus subject areas

  • Dermatology

Cite this